GuidelineHerzschrittmachertherapie & Elektrophysiologie2025
[Update of the ESC atrial fibrillation guidelines : From the DGK commission for clinical cardiovascular medicine].
Guideline in Herzschrittmachertherapie & Elektrophysiologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, the current ESC guidelines for the management of atrial fibrillation (AF) were published. Despite significant advances in the prevention, diagnosis and treatment of AF, it remains the most common sustained arrhythmia with a significant impact on patients, their caregivers and public health. The concise guidelines focus on evidence-based recommendations and their practical implementation supported by clear figures and treatment pathways. The holistic care for AF patients including their comorbidities is prioritized in a comprehensive AF-CARE concept. It comprises "C" for comorbidities and risk factor management, "A" for avoidance of stroke and thromboembolism, "R" for reduction of symptoms by rate and rhythm control and "E", evaluation and dynamic reassessment. Ablation is now the first-line therapy in paroxysmal AF. Current data on device detected AF and triggered AF are considered. Maximum involvement of the patient for informed, shared decision-making is suggested, supported by the parallel publication of patient guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.